| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Epstein-Barr Virus Antibody Panel
MessageSendout, Mayo test code: EBVAB
Test Code
LAB863
Alias/See Also
Anti EBV Serology
E. B. (Epstein-Barr) Virus
EBNA (Epstein-Barr Nuclear Antigen)
EBV (Epstein-Barr Virus) Battery
EBV (Epstein-Barr Virus) Panel
EBV (Epstein-Barr Virus)
EBV Panel, Serum
Epstein Barr Virus
Epstein-Barr Virus AB
Epstein-Barr Virus Battery
Epstein-Barr Virus Panel
VCA (Viral Capsid Antigen) IgG and IgM
Viral Capsid Antigen (VCA) Titer
Infectious Mononucleosis
EBV Ab, Serum
SEBV
EBVAB
E. B. (Epstein-Barr) Virus
EBNA (Epstein-Barr Nuclear Antigen)
EBV (Epstein-Barr Virus) Battery
EBV (Epstein-Barr Virus) Panel
EBV (Epstein-Barr Virus)
EBV Panel, Serum
Epstein Barr Virus
Epstein-Barr Virus AB
Epstein-Barr Virus Battery
Epstein-Barr Virus Panel
VCA (Viral Capsid Antigen) IgG and IgM
Viral Capsid Antigen (VCA) Titer
Infectious Mononucleosis
EBV Ab, Serum
SEBV
EBVAB
CPT Codes
86664, 86665x2
Preferred Specimen
1 mL serum from a gold serum gel tube
Minimum Volume
0.4 mL
Other Acceptable Specimens
Red tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Room Temperature
Specimen Stability
Refrigerated (preferred): 14 days
Frozen: 14 days
Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Heat-inactivated specimen: Reject
Gross lipemia: Reject
Gross icterus: Reject
Heat-inactivated specimen: Reject
Methodology
MEBV, GEBV, NAEBV: Enzyme-Linked Immunosorbent Assay (ELISA) INTEB: Technical Interpretation
FDA Status
Approved
Setup Schedule
Monday through Friday
Report Available
1-2 days
Limitations
Specimens collected too early during the course of the disease may not contain detectable antibodies to Epstein-Barr virus (EBV). Another specimen collected 1 to 2 weeks later may be required.
Test results should be evaluated in relation to patient symptoms, clinical history, and other laboratory findings.
The timing of the appearance of IgG antibodies to viral capsid antigen (VCA) or Epstein-Barr nuclear antigen or IgM antibodies to VCA is subject to variations among individuals and serological assays.
This assay's performance characteristics with immunosuppressed individuals, newborns, cord blood, or matrices other than human serum have not been established.
Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt lymphoma, and other EBV-associated lymphomas.
Anti-VCA-specific IgG may compete with IgM for binding sites, leading to false-negative results. Rheumatoid factor (RF), in the presence of specific IgG, may contribute to false-positive results. The absorbent in the VCA IgM diluent is intended to neutralize the effects of RF and specific IgG. Studies have shown that the absorbent was able to neutralize up to 98% of the activity in a specimen known to contain 3328 IU/mL of RF activity.
Testing for VCA IgM should not be performed as a screening procedure on the general population. The predictive value of positive or negative results depends on the pretest likelihood of Epstein-Barr-associated disease being present. Testing should only be performed when clinical evidence suggests the diagnosis of this syndrome.
Test results should be evaluated in relation to patient symptoms, clinical history, and other laboratory findings.
The timing of the appearance of IgG antibodies to viral capsid antigen (VCA) or Epstein-Barr nuclear antigen or IgM antibodies to VCA is subject to variations among individuals and serological assays.
This assay's performance characteristics with immunosuppressed individuals, newborns, cord blood, or matrices other than human serum have not been established.
Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt lymphoma, and other EBV-associated lymphomas.
Anti-VCA-specific IgG may compete with IgM for binding sites, leading to false-negative results. Rheumatoid factor (RF), in the presence of specific IgG, may contribute to false-positive results. The absorbent in the VCA IgM diluent is intended to neutralize the effects of RF and specific IgG. Studies have shown that the absorbent was able to neutralize up to 98% of the activity in a specimen known to contain 3328 IU/mL of RF activity.
Testing for VCA IgM should not be performed as a screening procedure on the general population. The predictive value of positive or negative results depends on the pretest likelihood of Epstein-Barr-associated disease being present. Testing should only be performed when clinical evidence suggests the diagnosis of this syndrome.
Reference Range
Included with report
Clinical Significance
Diagnosis of Epstein-Barr virus (EBV) infectious mononucleosis or other EBV related infections
Identification of prior EBV infection as part of pre-immunosuppression screening
This assay is not intended for viral isolation or identification.
Identification of prior EBV infection as part of pre-immunosuppression screening
This assay is not intended for viral isolation or identification.
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Epstein-Barr Virus Antibody Profile, Serum
